What did @dr.mohamed.gharibe actually say?
The video's caption, which serves as the primary content here, argues that exogenous testosterone shuts down the brain's signaling to the testes, causing testicular atrophy, and that HCG acts as a stand-in for that lost signal. In the creator's words, HCG "mimics the signal that comes from the brain" and functions as a kind of protective insurance against the side effects of TRT. The transcript itself was not clearly transcribed, so the caption is the substance we're working with.
This is a claim you hear constantly in TRT communities online, and it's not entirely wrong. But the framing as a simple "insurance policy" glosses over some real complexity about who actually needs HCG, what the evidence says about its benefits, and what the risks look like in a clinical context.
Does the science back this up?
Mostly, yes, but with important caveats. The core mechanism is accurate. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing or eliminating LH secretion, which in turn causes the Leydig cells in the testes to go dormant. HCG binds to LH receptors and can partially restore intratesticular testosterone production.
The evidence for HCG preserving testicular volume during TRT is real. Coviello et al. (2005, Journal of Clinical Endocrinology and Metabolism) demonstrated that low-dose HCG co-administration maintained intratesticular testosterone concentrations in men on exogenous testosterone suppression. That study is foundational and has held up. However, the clinical benefit of maintaining testicular volume for men who are not trying to conceive is less clear. A 2013 review by Ramasamy et al. in Fertility and Sterility noted that while HCG restores testicular function, its routine use in men not seeking fertility preservation lacks strong outcome data. The "insurance" framing implies universal benefit, which the evidence does not fully support.
What did they get wrong (or right)?
They got the mechanism right. The HPG axis suppression explanation is accurate, and describing HCG as mimicking LH is a reasonable simplification for a general audience. Credit where it's due: this is better science communication than a lot of TRT content on TikTok, which tends to skip the biology entirely.
What the video gets wrong, or at least oversimplifies, is the implication that HCG is a straightforward protective add-on for everyone on TRT. There are real concerns here. HCG can elevate estradiol levels, which may require aromatase inhibitor management in some patients, adding another layer of hormonal complexity. Elevated estradiol from HCG use has been documented clinically (Hsieh et al., 2013, Journal of Urology). Additionally, HCG is not trivially available. In the U.S., the FDA removed compounded HCG from its list of permissible compounded drugs in 2020, creating access and regulatory complications. Calling it an "insurance policy" without noting these trade-offs is incomplete at best.
What should you actually know?
If fertility preservation is your goal while on TRT, HCG has real evidence behind it. That is the strongest clinical use case. For men who are not concerned with fertility and whose only concern is testicular size, the evidence that maintaining size translates into meaningful health outcomes is thin. Testicular atrophy during TRT is largely cosmetic for most patients, not a functional health crisis.
You should also know that HCG availability has changed. The 2020 FDA regulatory shift means many compounded HCG products operate in a gray area, and branded options like Pregnyl are expensive. This is not a minor footnote. A patient acting on this video's advice may find that following through is more complicated than the framing suggests.
Finally, HCG is not without side effects. Mood changes, injection site reactions, and estrogenic effects are documented. Anyone considering adding HCG to a TRT regimen should have that conversation with a licensed clinician who can monitor hormone panels, not just act on social media content.
- HCG's LH-mimicking mechanism is well-established science.
- The fertility preservation use case has the strongest evidence base.
- Estradiol elevation is a real and undermentioned risk of HCG co-administration.
- The "insurance for everyone" framing is not supported by current evidence.
- Regulatory and access issues around HCG are relevant and ignored in this video.